Data / Research funding / Multiple Sclerosis
Multiple Sclerosis: 505 NIH awards ($469.4M) to 139 organizations
505 NIH awards ($469.4M) in the NIH spending category Multiple Sclerosis, to 139 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 505 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Integration of immune cell subtypes across diseases & tissue | NIH | National Institute on Aging | 2021 to 2022 | $5,948,190 | September 30, 2018 | August 31, 2023 | DE JAGER, PHILIP L | reporter.nih.gov |
| The Role of B cells in the Origin and Progression of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $5,776,308 | May 1, 2019 | April 30, 2027 | HAUSER, STEPHEN L | reporter.nih.gov |
| Environmental Biosensors in the Oligodendrocyte Lineage | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $5,732,603 | May 15, 2019 | April 30, 2027 | CASACCIA, PATRIZIA | reporter.nih.gov |
| Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $5,233,917 | July 1, 2020 | June 30, 2026 | ONTANEDA, DANIEL | reporter.nih.gov |
| Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $5,027,415 | January 1, 2020 | December 31, 2025 | CALABRESI, PETER A | reporter.nih.gov |
| Neurovascular Interactions: Mechanisms, imaging, therapeutic potential | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $4,247,898 | September 1, 2016 | August 31, 2025 | AKASSOGLOU, KATERINA | reporter.nih.gov |
| High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,939,372 | April 15, 2021 | March 31, 2027 | LI, HONGMIN | reporter.nih.gov |
| Modulating Glial Fate and Function in Development and Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,751,910 | May 1, 2020 | April 30, 2028 | TESAR, PAUL JOSEPH | reporter.nih.gov |
| Reserve against Disability in Early Multiple Sclerosis (RADIEMS) Longitudinal Cohort Study | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,629,278 | July 11, 2016 | July 31, 2026 | SUMOWSKI, JAMES FRANCIS | reporter.nih.gov |
| Design and development of HDAC11-specific chemical inhibitors for disease treatments | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,482,034 | March 1, 2021 | February 28, 2027 | SETO, EDWARD | reporter.nih.gov |
| Defining mechanisms of disease and repair in a viral model of multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,467,101 | May 1, 2020 | April 30, 2029 | LANE, THOMAS E | reporter.nih.gov |
| Pathogenesis of Neurological Disability in Primary Diseases of Myelin | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,460,848 | December 1, 2016 | November 30, 2025 | TRAPP, BRUCE D | reporter.nih.gov |
| CAR-T cell treatment of CNS Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,403,175 | June 13, 2022 | May 31, 2027 | WU, GREGORY | reporter.nih.gov |
| Deciphering the role of noncoding variation in the pathogenesis of multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,077,928 | July 15, 2021 | June 30, 2027 | CIOFANI, MARIA | reporter.nih.gov |
| Innate immune regulation of neuroinflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,052,610 | June 1, 2021 | May 31, 2027 | SONNENBERG, GREGORY F | reporter.nih.gov |
| Cbfb in RORgt-regulated T cell function | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,010,210 | May 1, 2014 | May 31, 2029 | SUN, ZUOMING | reporter.nih.gov |
| Optimizing detection and prediction of changes in cognitive function in multiple sclerosis with novel ambulatory assessment methods | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,003,354 | August 1, 2021 | July 31, 2027 | KRATZ, ANNA LOUISE | reporter.nih.gov |
| Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics with Multiple Sclerosis | NIH | National Institute on Minority Health and Health Disparities | 2025 | $2,825,047 | September 14, 2025 | June 30, 2029 | GEE, STEPHANIE SILVEIRA | reporter.nih.gov |
| Toward a Validated in Vivo Imaging Marker of Axonal Damage Predictive of Progressive Disability in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,805,313 | April 1, 2021 | March 31, 2027 | HUANG, SUSIE YI | reporter.nih.gov |
| Mechanisms of cannabidiol in persons with MS: the role of sleep and pain phenotype | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,725,289 | August 15, 2021 | May 31, 2026 | BRALEY, TIFFANY JOY | reporter.nih.gov |
| Home-based actigraphy to predict disability progression and enhance clinical trials in multiple sclerosis | NIH | National Institute of Nursing Research | 2021 to 2024 | $2,708,611 | September 7, 2020 | June 30, 2026 | MOWRY, ELLEN M. | reporter.nih.gov |
| Neurodegeneration Underlying Distinct Disabilities in Multiple Sclerosis Using a Cell-Specific, Region-Specific, and Sex-Specific Approach | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,697,814 | May 15, 2023 | April 30, 2031 | VOSKUHL, RHONDA R | reporter.nih.gov |
| Immunology of advancing disease among minorities with Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,692,372 | July 1, 2021 | May 31, 2027 | MONSON, NANCY L | reporter.nih.gov |
| Generating spatial and functional maps of cell-to-cell interactions in MS lesions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,587,248 | March 15, 2021 | February 28, 2026 | PITT, DAVID | reporter.nih.gov |
| Sustained Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $2,527,179 | April 15, 2019 | August 31, 2025 | WATKINS, GREGORY | reporter.nih.gov |
| Imaging Neurodegeneration in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,478,045 | April 1, 2013 | June 30, 2029 | SAIDHA, SHIV | reporter.nih.gov |
| PET Sphingosine-1-Phosphate Receptor 1 (S1P1) radiotracer for inflammation response in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,465,277 | September 30, 2017 | May 31, 2028 | TU, ZHUDE | reporter.nih.gov |
| Tolerance-programming biomaterial-based Intranasal ASIT for the treatment of autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,456,250 | September 15, 2021 | August 31, 2026 | WILSON, DAVID SCOTT | reporter.nih.gov |
| Defining how TCR strength of signal modulates Treg function | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,454,919 | September 19, 2022 | July 31, 2027 | EVAVOLD, BRIAN D | reporter.nih.gov |
| How do CNS fibroblasts regulate the response to neuroinflammation? | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,446,884 | January 1, 2021 | December 31, 2025 | DANEMAN, RICHARD | reporter.nih.gov |
| A Toolkit for Analysis and Visualization of Preclinical Rodent Neuroimaging Experiments | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,445,717 | April 1, 2022 | March 31, 2027 | SHATTUCK, DAVID W | reporter.nih.gov |
| Mechanisms by which effector T cells modulate endogenous remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,434,021 | July 1, 2000 | November 30, 2026 | CALABRESI, PETER A | reporter.nih.gov |
| Characterization of T cells in MOG antibody-associated disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,432,350 | July 1, 2023 | June 30, 2028 | ZAMVIL, SCOTT S | reporter.nih.gov |
| Pooled analysis of multiple sclerosis findings on multi-site 7 Tesla MRI | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,425,431 | July 1, 2021 | June 30, 2027 | HARRISON, DANIEL M | reporter.nih.gov |
| Statistical Methods for Multilevel Multivariate Functional Studies | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,357,762 | January 1, 2009 | June 30, 2027 | CRAINICEANU, CIPRIAN M | reporter.nih.gov |
| Neuronal antigen surveillance and autoimmunity in CNS demyelinating disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,354,214 | July 15, 2020 | April 30, 2025 | HOWE, CHARLES LEE | reporter.nih.gov |
| Muscle building supplement HMB for remyelination | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $2,347,150 | July 1, 2020 | June 30, 2025 | PAHAN, KALIPADA | reporter.nih.gov |
| Glial Mechanisms Governing the Removal and Repair of Degenerating Myelin | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,312,213 | September 1, 2021 | August 31, 2026 | HILL, ROBERT A. | reporter.nih.gov |
| Role of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease Course | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,281,489 | September 19, 2022 | July 31, 2028 | HOLLENBACH, JILL ALLISON | reporter.nih.gov |
| High-Intensity, dynamic-stability gait training in people with multiple sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,280,989 | September 15, 2022 | June 30, 2027 | SCHMIT, BRIAN D | reporter.nih.gov |
| Advanced Statistical Analytics of MRI in MS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,257,955 | April 1, 2020 | January 31, 2026 | SHINOHARA, RUSSELL TAKESHI | reporter.nih.gov |
| Interrogating the intersection between diet and ocular autoimmunity | NIH | National Eye Institute | 2022 to 2025 | $2,251,397 | April 1, 2022 | March 31, 2027 | PLAFKER, SCOTT M | reporter.nih.gov |
| Virtual Histology for Assessing MS Pathologies | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,247,732 | December 1, 2020 | November 30, 2025 | SONG, SHENG-KWEI | reporter.nih.gov |
| Targeting the Integrated Stress Response to Protect Oligodendrocyte lineage Cells | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,231,775 | December 1, 1996 | December 31, 2024 | POPKO, BRIAN J | reporter.nih.gov |
| Binding of Epstein Barr Virus EBNA2 Unifies Multiple Sclerosis Genetic Mechanisms | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,229,920 | April 15, 2017 | March 31, 2028 | WEIRAUCH, MATTHEW TYSON | reporter.nih.gov |
| Metabolic regulators of Treg/Th17 balance in CNS autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,226,462 | September 21, 2022 | July 31, 2027 | KUCHROO, VIJAY K. | reporter.nih.gov |
| Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depots | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,215,775 | February 1, 2022 | January 31, 2027 | JEWELL, CHRISTOPHER M | reporter.nih.gov |
| Clinical and Economic Impact of Teleneurology vs Standard in Clinic Care for Multiple Sclerosis: A Randomized Trial | NIH | National Institute of Nursing Research | 2022 to 2025 | $2,209,310 | September 26, 2022 | June 30, 2027 | MCGINLEY, MARISA | reporter.nih.gov |
| How Do Synaptic Connections Change in Demyelinating Disease? | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,182,790 | February 1, 2021 | January 31, 2026 | SCHAFER, DOROTHY PATRICIA | reporter.nih.gov |
| Beyond ganglion cells: Novel foveal avascular zone features in MS with implications for vision loss | NIH | National Eye Institute | 2022 to 2025 | $2,132,927 | September 30, 2022 | May 31, 2027 | MOSS, HEATHER ELSPETH | reporter.nih.gov |
| The role of myelination in cortical circuit function and motor behavior | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,128,733 | February 1, 2020 | December 31, 2029 | WELLE, CRISTIN G | reporter.nih.gov |
| A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,090,261 | April 24, 2023 | June 30, 2027 | FURLAN FREGUIA, CHRISTIAN | reporter.nih.gov |
| Neuronal responses to chronic demyelination | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,087,270 | April 1, 2021 | January 31, 2026 | EMERY, BEN | reporter.nih.gov |
| Novel mouse models to dissect the role of genetics, sex, and environment in heterogeneous outcomes in CNS autoimmune disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,079,892 | August 9, 2022 | July 31, 2027 | KREMENTSOV, DIMITRY N | reporter.nih.gov |
| Controlling the flux of sphingosine-1-phosphate in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,068,386 | January 15, 2019 | December 31, 2024 | LYNCH, KEVIN R. | reporter.nih.gov |
| From single molecule to microfluidic 3D tissue platforms: novel multiscale tools to investigate hyper-stimulated immune cells in the circulation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,067,484 | April 1, 2018 | May 31, 2029 | SPENCE, DANA M | reporter.nih.gov |
| Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through IND enabling studies and translational mouse models for acute disseminated encephalomyelitis (ADEM) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,050,000 | July 2, 2024 | June 30, 2026 | SCHULTZ, KENNETH | reporter.nih.gov |
| Molecular Mechanisms of IL-17-dependent autoimmune signaling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,039,628 | December 5, 2019 | November 30, 2025 | GAFFEN, SARAH L | reporter.nih.gov |
| The curious case of PARP1 in CNS myelin formation and repair | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,009,797 | July 1, 2022 | June 30, 2027 | GUO, FUZHENG | reporter.nih.gov |
| Immune Privilege, CNS Autoimmunity, and Clostridium perfringens Epsilon Toxin | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,004,200 | June 1, 2023 | May 31, 2028 | ANRATHER, JOSEF | reporter.nih.gov |
| Transcriptional Checkpoints Of Autoimmune Encephalomyelitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,003,720 | December 20, 2019 | November 30, 2025 | JORDAN, MARTHA S | reporter.nih.gov |
| Brain Predictors of Mobility and Falls in Older Adults with Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $2,002,271 | May 15, 2019 | February 28, 2025 | HOLTZER, ROEE | reporter.nih.gov |
| Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,993,412 | February 1, 2016 | March 31, 2025 | SHIRLEY, RENEE LYNN | reporter.nih.gov |
| Protective role of Clec7a/dectin-1 in CNS autoimmunity | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,992,768 | December 15, 2020 | November 30, 2025 | SHINOHARA, MARI L. | reporter.nih.gov |
| Tissue-Specific Mechanisms of Regulatory T Cells in the CNS during Autoimmune Encephalomyelitis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,988,640 | March 1, 2022 | February 28, 2027 | OTHY, SHIVASHANKAR | reporter.nih.gov |
| The role of the astrocyte immunoproteasome during chronic CNS autoimmunity | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,960,175 | December 1, 2020 | November 30, 2026 | WILLIAMS, JESSICA L | reporter.nih.gov |
| Pericyte-Macrophage Interactions Maintain CNS Immune Tolerance | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,959,759 | July 15, 2021 | May 31, 2026 | FILIANO, ANTHONY J | reporter.nih.gov |
| DNA methylation in the development of multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,955,277 | May 15, 2023 | April 30, 2027 | OKSENBERG, JORGE R. | reporter.nih.gov |
| Dissect and target Arginine-polyamine metabolic axis in T cell mediated inflammation and autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,947,250 | August 15, 2015 | March 31, 2026 | WANG, RUONING | reporter.nih.gov |
| CNS Demyelination: Initiation, Protection, and Correction | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,942,341 | May 15, 2024 | April 30, 2032 | POPKO, BRIAN J | reporter.nih.gov |
| Mesoscopic Biomarkers of Neurodegeneration and Inflammation with Diffusion MRI | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,935,529 | September 30, 2014 | July 31, 2025 | FIEREMANS, ELS | reporter.nih.gov |
| Microglial impact on remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,935,031 | June 15, 2020 | March 31, 2026 | MACKLIN, WENDY B | reporter.nih.gov |
| Functional protein networks underlying T cell growth, proliferation and differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,919,303 | December 12, 2016 | June 30, 2027 | WAN, YISONG | reporter.nih.gov |
| TGF-b superfamily signaling in controlling Th17 cell function in autoimmune neuroinflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,903,541 | January 16, 2021 | December 31, 2026 | WAN, YISONG | reporter.nih.gov |
| Decoding the language of inflammation between central nervous system resident immune cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,886,230 | June 7, 2021 | May 31, 2027 | CLARK, IAIN | reporter.nih.gov |
| Role of miRNA Dysregulation on T Cell Differentiation and Function in MS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,852,180 | February 3, 2020 | January 31, 2025 | LOVETT-RACKE, AMY E | reporter.nih.gov |
| The role of TNFR2 in ameliorating progressive encephalomyelitis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,839,850 | February 1, 2021 | December 31, 2026 | FORSTHUBER, THOMAS G. | reporter.nih.gov |
| Contribution of the effector Treg-B-antibody nexus to the regulation of CNS autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,834,380 | June 1, 2020 | May 31, 2026 | LEAVENWORTH, JIANMEI WU | reporter.nih.gov |
| Leveraging electronic health records to optimize treatment selection and response in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,834,204 | September 30, 2016 | December 31, 2027 | XIA, ZONGQI | reporter.nih.gov |
| Role of the neurovascular molecule Wnt in regulating CNS inflammatory responses | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,821,907 | August 1, 2022 | June 30, 2027 | IFERGAN, IGAL | reporter.nih.gov |
| Programmable Hydrogels for Optimized Human Oligodendrocyte Transplantation in Demyelinating Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,806,203 | July 1, 2023 | June 30, 2028 | ANDREADIS, STELIOS T. | reporter.nih.gov |
| Understanding role of circadian disruption in pathogenesis of MS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,795,603 | March 1, 2022 | February 28, 2027 | DUTTA, RANJAN | reporter.nih.gov |
| OCT and OCTA image processing for retinal assessment of people with MS | NIH | National Eye Institute | 2021 to 2024 | $1,790,957 | March 1, 2021 | February 28, 2026 | PRINCE, JERRY L | reporter.nih.gov |
| Targeting TGFb/IFNy-IRF8 Signaling to Modulate Monocytes and their Crosstalk with Microglia and Astrocytes to Treat Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,786,458 | September 30, 2014 | March 31, 2030 | BUTOVSKY, OLEG | reporter.nih.gov |
| Evaluating Advanced Diffusion of the Human Spinal Cord: Application to MS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,781,759 | February 15, 2021 | January 31, 2026 | SMITH, SETH A | reporter.nih.gov |
| How Does Actin Disassembly Drive Myelin Wrapping? | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,749,805 | September 30, 2020 | August 31, 2025 | ZUCHERO, JOHN B | reporter.nih.gov |
| Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,743,943 | January 3, 2023 | December 31, 2027 | ROBINSON, WILLIAM H | reporter.nih.gov |
| Restoring Immune Tolerance in a Model of Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,740,026 | January 1, 2017 | January 31, 2028 | KEELER, GEOFFREY D | reporter.nih.gov |
| Promoting remyelination in multiple sclerosis by simultaneously modulating myelin debris clearance and myelin lipid synthesis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,728,925 | July 15, 2022 | April 30, 2027 | HU, JIAN | reporter.nih.gov |
| Identification of Regulatory Mechanisms Operating in Rare Pathogenic Astrocyte Subsets in Multiple Sclerosis with a Novel Genomic Technology | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,703,421 | August 1, 2023 | July 31, 2028 | ABATE, ADAM R. | reporter.nih.gov |
| The pathogenic role of miR-92a in the regulation of T helper cell responses in EAE and MS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,688,880 | March 1, 2020 | February 28, 2026 | GOPAL, MURUGAIYAN | reporter.nih.gov |
| In vivo three-photon microscopy of the cortical gray and white matter | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,631,509 | July 1, 2023 | May 31, 2028 | HUGHES, ETHAN GARRETT | reporter.nih.gov |
| MR Metabolic Imaging of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,618,501 | September 1, 2017 | June 30, 2028 | GORDON, JEREMY WILLIAM | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis | NIH | National Eye Institute | 2022 to 2025 | $1,606,501 | September 30, 2022 | January 31, 2026 | SCHULTZ, KENNETH | reporter.nih.gov |
| Targeting OCA-B in multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,605,448 | February 11, 2022 | January 31, 2027 | TANTIN, DEAN | reporter.nih.gov |
| DYNAMICS AND TUNING OF THE MHC II PRESENTED PEPTIDOME | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,603,685 | September 19, 2018 | August 31, 2025 | SANTAMBROGIO, LAURA | reporter.nih.gov |
| New sterol-binding targets and optimized EBP inhibitors for promoting remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,598,057 | May 1, 2020 | January 31, 2025 | ADAMS, DREW JAMES | reporter.nih.gov |
| Mechanisms of retinal degeneration in neuroinflammatory demyelinating diseases | NIH | National Eye Institute | 2021 to 2024 | $1,597,925 | January 1, 2021 | November 30, 2025 | DESILVA, TARA MARIA | reporter.nih.gov |
| Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,594,440 | January 25, 2019 | December 31, 2025 | CHEN, MINGNAN | reporter.nih.gov |
| Novel Pathways to Excitotoxicity in Multiple Sclerosis Caused by Inappropriate Intrusion of an Axonal Mitochondrial Anchor Syntaphilin into Dendrites | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,587,045 | August 1, 2020 | June 30, 2025 | CHIU, SHING YAN | reporter.nih.gov |
| Mechanism underlying regulation of Ca2+ signaling in local effector T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,560,000 | March 5, 2020 | February 28, 2026 | GWACK, YOUSANG | reporter.nih.gov |
| IL-37: a novel regulator of inflammation in CNS autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,560,000 | March 11, 2021 | February 28, 2027 | ROSTAMI, A.M. | reporter.nih.gov |
| ThGM Cells in CNS Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,560,000 | July 12, 2021 | June 30, 2027 | ROSTAMI, A.M. | reporter.nih.gov |
| Investigating Genetic and Epigenetic Control of T Cell Function in Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $1,559,700 | September 8, 2023 | August 31, 2026 | RAY, JOHN PHILIP | reporter.nih.gov |
| Demyelination is coupled to neuronal hyperexcitability leading to seizures | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,553,622 | February 1, 2020 | January 31, 2026 | TIWARI-WOODRUFF, SEEMA K | reporter.nih.gov |
| Role of IL-7R in CNS autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,548,300 | December 1, 2020 | November 30, 2026 | ROSTAMI, A.M. | reporter.nih.gov |
| Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,548,300 | March 1, 2020 | February 28, 2027 | ROSTAMI, A.M. | reporter.nih.gov |
| A TCF1:Glucocorticoid regulatory circuit controls IL-23-driven Th17 pathogenicity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,537,521 | February 1, 2023 | January 31, 2028 | ANDERSON, ANA C | reporter.nih.gov |
| Precision of Myelin Plasticity in Health and Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,516,915 | December 1, 2021 | November 30, 2026 | HUGHES, ETHAN GARRETT | reporter.nih.gov |
| Deep Gray Matter Iron and Disease Progression in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,515,447 | July 1, 2021 | June 30, 2025 | SCHWESER, FERDINAND | reporter.nih.gov |
| Novel molecular mediators for activity-dependent myelination | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,513,389 | June 1, 2022 | May 31, 2027 | SUN, WENJING | reporter.nih.gov |
| Regulatory mechanisms governing Th17 cell effector identity and plasticity | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,502,098 | April 1, 2016 | March 31, 2026 | CIOFANI, MARIA | reporter.nih.gov |
| Regulation of B cells in the CNS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,502,050 | September 15, 2013 | March 31, 2026 | BERGMANN, CORNELIA | reporter.nih.gov |
| Regulation of B cell function in demyelinating disease by N-glycan branching | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,501,509 | January 14, 2019 | December 31, 2024 | DEMETRIOU, MICHAEL | reporter.nih.gov |
| Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,499,167 | February 10, 2023 | January 31, 2028 | WANG, RUONING | reporter.nih.gov |
| Role of AHR in Dendritic Cells in the Control of CNS Autoimmunity | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $1,488,684 | June 1, 2016 | November 30, 2026 | QUINTANA, FRANCISCO J. | reporter.nih.gov |
| Imaging B cells in the brain and beyond: developing an immuno-PET toolbox to improve understanding and treatment of multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,472,840 | July 15, 2020 | April 30, 2026 | JAMES, MICHELLE LOUISE | reporter.nih.gov |
| Integrated, dynamic B0 and flip-angle shimming using multi-coil shim arrays | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $1,445,862 | March 1, 2024 | August 31, 2028 | GUERIN, BASTIEN | reporter.nih.gov |
| Gliovascular Mechanisms of Blood-Brain Barrier Disruption in Neuroinflammatory Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,438,273 | August 1, 2019 | April 30, 2025 | DAVALOS, DIMITRIOS | reporter.nih.gov |
| Can [18F]3F4AP Detect Brain Demyelination? Evaluation of Novel PET Tracer in Nonhuman Primates and Humans | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,426,088 | December 15, 2019 | November 30, 2025 | BRUGAROLAS, PEDRO | reporter.nih.gov |
| Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $1,418,318 | September 1, 2021 | July 31, 2027 | MOTL, ROBERT WAYNE | reporter.nih.gov |
| Pathogenic B cell:CD4 T cell interactions in a novel B cell-dependent EAE mouse model of multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,417,107 | August 17, 2023 | July 31, 2028 | BOYDEN, ALEXANDER | reporter.nih.gov |
| Development of a novel accurate therapy for multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,403,826 | January 22, 2019 | July 31, 2025 | GALARZA-MUNOZ, GADDIEL | reporter.nih.gov |
| High-spatial-resolution multi-omics sequencing of brain lesions in multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,397,255 | August 16, 2023 | July 31, 2028 | DENG, YANXIANG | reporter.nih.gov |
| SNARE complex-mediated exocytosis in oligodendrocyte differentiation and survival | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,385,304 | April 1, 2020 | March 31, 2026 | NISHIYAMA, AKIKO | reporter.nih.gov |
| Myelin oligodendrocyte glycoprotein antibody disease: incidence, prevalence, outcome prediction and immunopathology | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,378,600 | December 1, 2019 | November 30, 2024 | FLANAGAN, EOIN P | reporter.nih.gov |
| Neurovascular Interactions: Mechanisms, Imaging, Therapeutics | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,375,478 | September 1, 2025 | August 31, 2033 | AKASSOGLOU, KATERINA | reporter.nih.gov |
| Spinal cord functional connectivity as a biomarker of spinal cord dysfunction | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $1,373,657 | June 1, 2019 | February 29, 2024 | BARRY, ROBERT L | reporter.nih.gov |
| Biosynthesis and biological mechanism of minor cannabinoids | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $1,373,136 | December 20, 2023 | October 31, 2028 | MOORE, BRADLEY S | reporter.nih.gov |
| MS Falls InsightTrack (MS FIT): A personal health library to reduce falls in patients with MS | NIH | National Library of Medicine | 2021 to 2024 | $1,372,752 | September 1, 2021 | May 31, 2026 | BOVE, RILEY MARIE BROWNE | reporter.nih.gov |
| Multi-Scale, Multi-Modal Imaging Assessment of Trajectories of Cognitive Impairment in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,361,648 | August 8, 2024 | July 31, 2029 | GAUTHIER, SUSAN A | reporter.nih.gov |
| Sur1-Trpm4 regulation of the pro-inflammatory astrocytic secretome in EAE | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,341,737 | February 15, 2020 | January 31, 2026 | GERZANICH, VLADIMIR | reporter.nih.gov |
| Contribution of plasmablasts in the conversion of transverse myelitis to multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,340,203 | April 15, 2018 | March 31, 2024 | MONSON, NANCY L | reporter.nih.gov |
| Cortical Demyelination and Repair in Early Multiple Sclerosis. | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,337,770 | August 1, 2024 | June 30, 2029 | BECK, ERIN SAVNER | reporter.nih.gov |
| Defining the contribution of astrocytes to genetic MS susceptibility | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,316,196 | May 1, 2019 | March 31, 2024 | PITT, DAVID | reporter.nih.gov |
| Mechanisms for matrix-dependent BBB dysfunction | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,310,795 | July 1, 2020 | April 30, 2025 | BEARD, RICHARD SCOTT | reporter.nih.gov |
| Pathogenic Astrocyte Populations in EAE and MS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,306,944 | July 6, 2023 | April 30, 2028 | QUINTANA, FRANCISCO J. | reporter.nih.gov |
| Evaluating the therapeutic potential of hypoxia mimetics in inflammatory demyelinating disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,302,208 | August 1, 2024 | June 30, 2029 | MILNER, D. RICHARD | reporter.nih.gov |
| ATP1B3: novel regulator of T cell-mediated immunity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,254,955 | August 15, 2024 | July 31, 2029 | FESKE, STEFAN | reporter.nih.gov |
| Mechanisms linking hemostatic factors and neuroinflammatorydisease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,237,062 | March 1, 2019 | February 28, 2025 | MULLINS, ERIC S | reporter.nih.gov |
| Quantification of Multi-Compartment T1 Relaxation and Magnetization Transfer in Biological Tissue: From Biophysics to Biomarkers for Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,232,113 | December 1, 2023 | November 30, 2028 | ASSLAENDER, JAKOB | reporter.nih.gov |
| Defining how phospholipid signaling networks control Th17 differentiation and effector function | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,229,455 | December 1, 2023 | October 31, 2028 | HAWSE, WILLIAM FRANCIS | reporter.nih.gov |
| Metabolic predictors of disease outcomes in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,225,466 | February 15, 2024 | January 31, 2029 | FITZGERALD, KATHRYN C. | reporter.nih.gov |
| No-Gd MRI for Monitoring Disease Status in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,208,258 | September 30, 2018 | August 31, 2024 | WANG, YI | reporter.nih.gov |
| Mechanisms of oligodendroglial ciliary function in white matter injury repair | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,199,138 | April 15, 2023 | March 31, 2028 | FANCY, STEPHEN PHILIP JAMES | reporter.nih.gov |
| Real-world impact of the COVID-19 pandemic in people with multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $1,195,081 | January 15, 2022 | June 30, 2025 | XIA, ZONGQI | reporter.nih.gov |
| Subjective Valuation of Physical Effort in Health and Disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,190,950 | September 1, 2019 | June 30, 2025 | CHIB, VIKRAM S | reporter.nih.gov |
| SOX2-regulated astrocyte homeostasis and pathophysiology | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,188,489 | January 1, 2024 | December 31, 2028 | GUO, FUZHENG | reporter.nih.gov |
| Novel Regulation and Targeting of Macrophages Metabolism in Neuroinflammatory Disorders | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,187,073 | February 4, 2019 | January 31, 2025 | GIRI, SHAILENDRA | reporter.nih.gov |
| In vivo assessment of meningeal inflammation and its clinical impact in multiple sclerosis by 7 Tesla MRI | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,181,844 | February 1, 2018 | June 30, 2024 | HARRISON, DANIEL M | reporter.nih.gov |
| Molecular regulation of TLR2-mediated autoimmune inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,170,000 | November 15, 2018 | October 31, 2025 | REYNOLDS, JOSEPH MICHAEL | reporter.nih.gov |
| ICLIC-MS for Enhancing Outcomes Research and Clinical Care in Multiple Sclerosis | NIH | National Institute of Nursing Research | 2021 to 2022 | $1,164,856 | August 14, 2018 | May 31, 2024 | BARCELLOS, LISA F | reporter.nih.gov |
| Quantification of the Innate Immune Activity within Chronic Lesions as a Novel Treatment Biomarker in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,155,493 | April 1, 2024 | March 31, 2029 | GAUTHIER, SUSAN A | reporter.nih.gov |
| Multiple sclerosis as a cytodegenerative proteopathy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,142,538 | February 1, 2022 | January 31, 2027 | STYS, PETER K | reporter.nih.gov |
| Characterizing the serum metabolome in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,128,855 | April 15, 2021 | August 6, 2023 | BRIGGS, FARREN B. S. | reporter.nih.gov |
| Targeting professional APCs using Fasciola hepatica FABP to suppresses inflammation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,106,359 | August 1, 2020 | July 31, 2025 | ESPINO, ANA M | reporter.nih.gov |
| Metabolic correlates of disease activity and disability progression in pediatric MS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,103,912 | April 1, 2021 | March 31, 2024 | WAUBANT, EMMANUELLE LAURENCE | reporter.nih.gov |
| Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $1,072,291 | May 10, 2019 | September 30, 2025 | CHIARAVALLOTI, NANCY D. | reporter.nih.gov |
| T cell-dependent regulation of microglia demyelinating functions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,056,564 | March 1, 2019 | January 31, 2025 | BERGMANN, CORNELIA | reporter.nih.gov |
| Transcriptional Determinants of the Fate Trajectories of Single Human Glial Progenitor Cells in Response to Demyelination in Vivo | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,051,297 | April 1, 2019 | January 31, 2025 | GOLDMAN, STEVEN ALAN | reporter.nih.gov |
| A randomized, sham-controlled clinical trial evaluating individualized neuromodulation of cortical regions involved in neurogenic overactive bladder in Multiple Sclerosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,039,129 | January 24, 2023 | December 31, 2027 | KHAVARI, ROSE | reporter.nih.gov |
| STAT5 Tetramerization in Autoimmune-mediated Neuroinflammation | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,025,976 | January 17, 2024 | November 30, 2028 | WAN, EDWIN CHI KEUNG | reporter.nih.gov |
| Non-invasive imaging of brain infiltrating T lymphocytes in a mouse model of experimental autoimmune encephalomyelitis with PET | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $999,537 | May 15, 2019 | February 29, 2024 | CLARK, PETER MICHAEL | reporter.nih.gov |
| Mechanisms underlying regulation of injured axons in CNS autoimmunity | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $990,146 | December 15, 2023 | November 30, 2028 | GU, CHEN | reporter.nih.gov |
| Endogenous metabolite restricts GM-CSF signaling pathway in pathogenic macrophages to ameliorate CNS Autoimmunity | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $987,657 | June 15, 2019 | March 31, 2025 | GIRI, SHAILENDRA | reporter.nih.gov |
| Multivariate machine learning analysis of blood-based RNA expression profiles to distinguish relapsing-remitting and progressive forms of multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $979,138 | August 1, 2025 | July 31, 2027 | SPURLOCK, CHARLES FLOYD | reporter.nih.gov |
| Regulation of encephalitogenic T cells by CRAC channels | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $977,967 | September 14, 2018 | August 31, 2023 | FESKE, STEFAN | reporter.nih.gov |
| Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $961,874 | December 1, 2020 | November 30, 2026 | BRENTON, JAMES NICHOLAS | reporter.nih.gov |
| Engineering an extracellular vesicle-based targeted regenerative nanotherapeutic for multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $952,355 | September 1, 2024 | August 31, 2029 | WANG, AIJUN | reporter.nih.gov |
| Multimodal, quantitative MRI in the lumbosacral spinal cord in progressive multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $944,624 | May 1, 2024 | April 30, 2028 | O'GRADY, KRISTIN POOLE | reporter.nih.gov |
| Supplement to Immunological Niches and Noninvasive Biosensors for Autoimmune Monitoring | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $912,215 | January 1, 2025 | May 31, 2026 | MORRIS, AARON HARVEY | reporter.nih.gov |
| Meningeal ectopic lymphoid tissues (mELTs): Composition, organization and expression revealed by imaging and in situ transcriptomics | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $902,721 | April 16, 2024 | March 31, 2027 | PACHTER, JOEL S | reporter.nih.gov |
| Role of type 2 Innate Lymphoid Cells (ILC2s) in optic neuritis | NIH | National Eye Institute | 2021 to 2022 | $893,981 | March 1, 2019 | February 29, 2024 | GHIASI, HOMAYON | reporter.nih.gov |
| Neuroprotection in MS: A Cell-Specific and Region-Specific Transcriptomics Approach | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $889,150 | September 30, 2018 | May 31, 2023 | VOSKUHL, RHONDA R | reporter.nih.gov |
| Development of Drugs that Modify CNS Innate Immunity for the Treatment of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $869,720 | April 15, 2022 | September 30, 2025 | QUINTANA, FRANCISCO J. | reporter.nih.gov |
| Mediterranean Diet, Biological Aging, and Risk for Disease and Disability Progression in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $866,969 | December 1, 2023 | November 30, 2027 | KATZ SAND, ILANA BETH | reporter.nih.gov |
| S1P signaling machinery in neuroimmune interactions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $853,126 | April 15, 2018 | January 31, 2024 | KIHARA, YASUYUKI | reporter.nih.gov |
| Role and Regulation of Neural Stem Cells in Remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $849,466 | June 1, 2018 | May 31, 2023 | SALZER, JAMES | reporter.nih.gov |
| Impact of the Gut Microbiome on Astrocyte Barrier Function | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $846,366 | September 1, 2023 | August 31, 2028 | TANKOU, STEPHANIE | reporter.nih.gov |
| A vasculo-protective role for beta4 integrin in neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $840,000 | December 1, 2018 | February 29, 2024 | MILNER, D. RICHARD | reporter.nih.gov |
| Multicomponent Modeling of High-Dimensional Multiparametric MRI Data | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 | $836,443 | August 1, 2023 | July 31, 2025 | HALDAR, JUSTIN PRITAM | reporter.nih.gov |
| COMPUTATIONAL TOOLS FOR THE ANALYSIS OF HIGH-THROUGHPUT IMMUNOGLOBULIN SEQUENCING EXPERIMENTS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $832,277 | April 15, 2014 | December 31, 2024 | KLEINSTEIN, STEVEN H. | reporter.nih.gov |
| Ligand-dependent and cell type-specific functions of integrin CD11b/CD18 in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $830,271 | September 15, 2019 | May 31, 2025 | ZHANG, LI | reporter.nih.gov |
| Validating Inhibitors of the Immunomodulatory Sphingosine 1-Phosphate Transporter SPNS2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $829,819 | March 1, 2020 | February 28, 2025 | SCHWAB, SUSAN RUTH | reporter.nih.gov |
| Imaging retinal leukocyte-endothelial interaction as a diagnostic marker for multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $826,560 | August 15, 2017 | June 30, 2023 | ALT, CLEMENS | reporter.nih.gov |
| MRI Paramagnetic Rim Lesions as Biomarkers and Agents of Neurodegeneration in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $824,222 | April 1, 2022 | March 31, 2027 | HEMOND, CHRISTOPHER C. | reporter.nih.gov |
| Contribution of antibodies targeting PLP1-anchored membrane domains to multiple sclerosis pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $812,097 | September 5, 2024 | August 31, 2029 | BENNETT, JEFFREY L | reporter.nih.gov |
| Head-neck RF coil with local field control for comprehensive high-resolution 7T neuro MRI exams | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $808,070 | August 1, 2025 | July 31, 2030 | STOCKMANN, JASON P | reporter.nih.gov |
| High Content Screening for Bifunctional Chimera Biologics | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $807,664 | January 1, 2025 | December 31, 2027 | VALENTE, LIZ | reporter.nih.gov |
| TNFR2 sex differences and EAE | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $807,500 | December 1, 2021 | November 30, 2026 | BETHEA, JOHN ROLAND | reporter.nih.gov |
| Characterization of Whole Brain Demyelination and Axon Damage Using High-resolution Magnetic Resonance Imaging | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $805,605 | May 30, 2024 | May 31, 2027 | WANG, NIAN | reporter.nih.gov |
| Targeting SNO-GAPDH in inflammatory neurodegeneration and mitochondrial injury | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $802,240 | December 1, 2019 | November 30, 2024 | KORNBERG, MICHAEL D | reporter.nih.gov |
| Characterization of Whole Brain Demyelination and Axon Damage Using High-resolution Magnetic Resonance Imaging | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $792,500 | June 1, 2022 | May 31, 2024 | WANG, NIAN | reporter.nih.gov |
| Developing Tolerization Therapies from a New T-cell Based Mouse Model of Neuromyelitis Optica | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $792,400 | May 25, 2018 | April 30, 2023 | LEVY, MICHAEL | reporter.nih.gov |
| Metabolic targeting of CD4 T cells in CNS autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $790,222 | July 8, 2025 | June 30, 2030 | JONES, RUSSELL GRAHAM | reporter.nih.gov |
| MRI-Based Quantitative Mapping of Oxygen Extraction Fraction in MS | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $788,743 | April 1, 2024 | March 31, 2029 | CHO, JUNGHUN | reporter.nih.gov |
| Development of Susceptibility Weighted MRI for the Human Spinal Cord | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $787,500 | March 1, 2024 | February 29, 2028 | SMITH, SETH A | reporter.nih.gov |
| The role of microglia in cortical remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $785,856 | April 16, 2024 | March 31, 2029 | ORTHMANN-MURPHY, JENNIFER LAUREN | reporter.nih.gov |
| Improving multiple sclerosis patient quality of life using microneedle patches to simplify delivery of MS drugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $784,202 | June 17, 2019 | May 31, 2024 | JEWELL, CHRISTOPHER M | reporter.nih.gov |
| Molecular Control of Astrocytes in CNS Inflammation | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $782,651 | August 15, 2020 | January 31, 2026 | WHEELER, MICHAEL ALEX | reporter.nih.gov |
| The Role of IL-II in the development of autoimmune response in multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $780,000 | July 11, 2018 | June 30, 2023 | MARKOVIC-PLESE, SILVA | reporter.nih.gov |
| Defining the Role of Molecules Unique to Encephalitogenic T Cells in MS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $780,000 | September 4, 2019 | August 31, 2023 | LOVETT-RACKE, AMY E | reporter.nih.gov |
| Alcohol's Impact on the Gut-Brain Axis in a Mouse Model of Multiple Sclerosis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $776,736 | August 5, 2020 | July 31, 2025 | MELAMED, ESTHER | reporter.nih.gov |
| Treadmill Walking Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: A Systematically-Developed Randomized Controlled Trial | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $769,232 | February 8, 2018 | August 31, 2024 | SANDROFF, BRIAN M | reporter.nih.gov |
| Novel Modulators of TGFß1 signaling in regulation of remyelination by neural stem cells | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $764,180 | January 1, 2022 | June 30, 2023 | SAMANTA, JAYSHREE | reporter.nih.gov |
| Elucidating the biological mechanisms underlying the association between EBV and MS in African Americans | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $763,865 | November 15, 2024 | October 31, 2029 | ASCHERIO, ALBERTO | reporter.nih.gov |
| Linking diet, gut microbiota and autoimmune disease: Bacteria induced phytoestrogen metabolites impact immune function in Experimental Autoimmune Encephalitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $762,500 | February 15, 2018 | January 31, 2023 | MANGALAM, ASHUTOSH KUMAR | reporter.nih.gov |
| TNFR2 Sex Differences and EAE | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $757,500 | December 1, 2021 | November 30, 2023 | BETHEA, JOHN ROLAND | reporter.nih.gov |
| Computational Imaging Biomarkers of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $754,447 | September 1, 2019 | May 31, 2024 | VAN LEEMPUT, KOEN | reporter.nih.gov |
| Biomaterials to study tolerance immune induction kinetics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $753,116 | August 14, 2018 | July 31, 2024 | AINSLIE, KRISTY M | reporter.nih.gov |
| Neuroinflammation-induced lymphangiogenesis in the CNS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $752,280 | September 1, 2018 | July 31, 2024 | FABRY, ZSUZSANNA | reporter.nih.gov |
| Prospective Study of Vitamin D and MS Risk in African Americans | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $747,193 | September 15, 2018 | May 19, 2025 | ASCHERIO, ALBERTO | reporter.nih.gov |
| Childhood Adversity Research Effort in Multiple Sclerosis (CARE.in.MS) | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $742,352 | December 9, 2024 | November 30, 2029 | KRUPP, LAUREN B | reporter.nih.gov |
| Damage Associated Molecular Patterns and Regenerative Failure in MS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $738,183 | December 1, 2017 | November 30, 2023 | VARTANIAN, TIMOTHY | reporter.nih.gov |
| Establishing VEP as a quantitative biomarker for remyelination using transgenic models for gain and loss of function | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $731,902 | May 15, 2018 | February 28, 2023 | GREEN, ARI J | reporter.nih.gov |
| Developing Remyelination Strategies for Demyelinating Optic Neuropathies Using Human Pluripotent Stem Cells | NIH | National Eye Institute | 2022 to 2024 | $730,625 | January 1, 2022 | December 31, 2024 | CHAMLING, XITIZ | reporter.nih.gov |
| Reporting Quantitative Microstructural MRI Metrics to Stage and Monitor Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $718,827 | September 10, 2024 | August 31, 2026 | LEMBERSKIY, GRIGORIY | reporter.nih.gov |
| Prediction of risk of disability worsening and inflammatory disease activity in MS utilizing multimodal prediction algorithms | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $718,628 | August 1, 2020 | July 31, 2025 | SOTIRCHOS, ELIAS S | reporter.nih.gov |
| Control of Local CNS Inflammation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $716,766 | September 1, 2018 | August 31, 2024 | QUINTANA, FRANCISCO J. | reporter.nih.gov |
| Understanding the roles type I Interferon and TH17 play in Neuromyelitis Optica and other autoimmune diseases. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $700,785 | August 1, 2018 | July 31, 2023 | AXTELL, ROBERT C | reporter.nih.gov |
| Reversible mRNA methylation in oligodendrocyte development and CNS myelination | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $699,636 | January 1, 2020 | July 31, 2024 | POPKO, BRIAN J | reporter.nih.gov |
| PET and MRI Evaluation of Cerebral Inflammation and Metabolic Stress in Relapsing Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $698,727 | July 15, 2023 | June 30, 2028 | BRIER, MATTHEW RYAN | reporter.nih.gov |
| Muscarinic Receptor Type 3 Regulation of Oligodendrocyte Progenitor Differentiation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $697,812 | December 1, 2017 | November 30, 2023 | SIM, FRASER JAMES | reporter.nih.gov |
| Novel Modulators of TGFß1 signaling in regulation of remyelination by neural stem cells | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $692,723 | January 1, 2022 | November 30, 2026 | SAMANTA, JAYSHREE | reporter.nih.gov |
| Interferon beta modulates neuroinflammation and extends tPA therapeutic window in ischemic stroke | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $689,062 | June 15, 2018 | October 30, 2024 | YEN, JUI-HUNG JIMMY | reporter.nih.gov |
| Structural and Functional MRI of the Cervical Spinal Cord in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $688,988 | September 15, 2018 | June 30, 2024 | SMITH, SETH A | reporter.nih.gov |
| Specialization and targeting of CD4+ tissue resident memory T cells in EAE | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $687,422 | July 22, 2025 | June 30, 2030 | BETTELLI, ESTELLE | reporter.nih.gov |
| Mechanisms of neurogenic bladder dysfunction in a viral murine model of multiple sclerosis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $684,200 | September 8, 2020 | October 31, 2024 | MALYKHINA, ANNA P | reporter.nih.gov |
| Immunoregulation in CNS remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $680,312 | July 1, 2018 | May 31, 2024 | HUANG, JEFFREY K | reporter.nih.gov |
| THE INTEGRATION OF IL-17 AND NOTCH SIGNALING IN THE PATHOGENESIS OF CNS INFLAMMATION | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $675,938 | March 1, 2021 | February 29, 2024 | KANG, ZIZHEN | reporter.nih.gov |
| Building and Validating Lifelong Self-Management Capacity with Advanced AI: MyMSMentor | NIH | National Library of Medicine | 2024 to 2025 | $658,692 | September 18, 2024 | August 31, 2028 | CHIU, CHUNG-YI | reporter.nih.gov |
| Disease modifying therapies, serum neurofilament light chain levels, and multiple sclerosis outcomes in Black and Hispanic persons | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $657,841 | August 4, 2025 | July 31, 2030 | LANGER-GOULD, ANNETTE M | reporter.nih.gov |
| Computational Model of Neurocognitive Impairment in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $654,287 | April 1, 2025 | February 28, 2030 | SUMOWSKI, JAMES FRANCIS | reporter.nih.gov |
| Non-invasive Imaging of Pathological Fibrin Deposition and its Effect on Progressive Neurodegeneration in the Human Brain: an in vivo longitudinal study | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $653,192 | July 18, 2025 | June 30, 2030 | MAINERO, CATERINA | reporter.nih.gov |
| Mechanisms of alpha-synuclein mediated inflammation in multiple system atrophy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $649,688 | June 1, 2018 | March 31, 2024 | HARMS, ASHLEY N | reporter.nih.gov |
| Control of regulatory T cell fitness and function by heme synthesis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $647,187 | July 3, 2025 | June 30, 2030 | LI, XUDONG | reporter.nih.gov |
| Aerobic exercise to improve mobility in multiple sclerosis: optimizing design and execution for a full-scale multimodal remyelination clinical trial | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $638,916 | July 1, 2020 | June 30, 2025 | WOOLISCROFT, LINDSEY BRIANNA | reporter.nih.gov |
| Identification of a novel pathway that regulates optic nerve myelination and remyelination | NIH | National Eye Institute | 2021 to 2022 | $634,755 | July 1, 2020 | June 30, 2023 | SUN, LU | reporter.nih.gov |
| Development of 18F PET radiotracers for M2 microglia as diagnostics for multiplesclerosis pathogenesis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $633,440 | September 15, 2022 | December 31, 2025 | STUPPLE, PAUL ANTHONY | reporter.nih.gov |
| MHC variation at high resolution in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $632,927 | August 15, 2017 | April 30, 2022 | OKSENBERG, JORGE R. | reporter.nih.gov |
| STAT4 regulation of Th17 pathogenicity | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $632,423 | August 1, 2025 | July 31, 2030 | HARRINGTON, LAURIE ELLEN | reporter.nih.gov |
| Tissue Cytokine Sequestration and Immune Regulation in Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $632,042 | July 1, 2012 | June 30, 2022 | BOLLYKY, PAUL L | reporter.nih.gov |
| Microstructure and connectivity modeling from the cortex to the spinal cord in Multiple Sclerosis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $630,048 | June 1, 2022 | February 28, 2027 | SCHILLING, KURT G | reporter.nih.gov |
| Targeting Cholesterol Homeostasis to maintain vision in MS-like optic neuritis | NIH | National Eye Institute | 2023 to 2024 | $630,000 | August 1, 2023 | March 31, 2028 | GRAMLICH, OLIVER W | reporter.nih.gov |
| Non-invasive and Long-lived CNS Delivery of Treg-inducing Cytokine Depots | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $623,579 | February 1, 2025 | January 31, 2029 | TESSIER, PETER M | reporter.nih.gov |
| Molecular Mechanisms of Oligodendrocyte Myelination and remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $614,009 | June 15, 2025 | April 30, 2030 | LU, QING RICHARD | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $610,850 | June 21, 2023 | May 31, 2025 | SCHULTZ, KENNETH | reporter.nih.gov |
| Genetic and Phenotypic Analysis of Multiple Sclerosis in Hispanics | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $607,398 | August 1, 2016 | May 31, 2023 | MCCAULEY, JACOB L | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $601,607 | August 1, 2023 | July 31, 2025 | SCHULTZ, KENNETH | reporter.nih.gov |
| Detection of disease-relevant CD8+ T cells in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $600,534 | July 1, 2019 | June 30, 2025 | SABATINO, JOSEPH JOHN | reporter.nih.gov |
| Efficacy of NSCs in an EAE model of MS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $600,000 | May 15, 2022 | April 30, 2027 | CHAUDHRY, G. RASUL | reporter.nih.gov |
| Interactions between Gut Microbiome and B-Cell Depletion in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $588,059 | July 1, 2019 | June 30, 2025 | LONGBRAKE, ERIN | reporter.nih.gov |
| Depression as a disease of network disruption: learning from multiple sclerosis | NIH | National Institute of Mental Health | 2023 to 2025 | $584,820 | July 1, 2023 | June 30, 2028 | BALLER, ERICA BERLIN | reporter.nih.gov |
| Oral autoantigen therapy for the treatment of Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $583,553 | January 22, 2021 | December 31, 2024 | PILLER, KENNETH J | reporter.nih.gov |
| Molecular and genetic regulation of myelin capacity in the CNS | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $576,142 | June 19, 2025 | March 31, 2030 | MONK, KELLY R | reporter.nih.gov |
| Racial Disparities in Multiple Sclerosis: Quality of Care and Patient Experiences | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $568,169 | September 23, 2019 | June 30, 2025 | BHATTARAI, JAGRITI JACKIE | reporter.nih.gov |
| Effects of tobacco smoking on prognosis and immune function in multiple sclerosis | NIH | National Institute on Drug Abuse | 2025 | $552,147 | June 1, 2025 | February 28, 2030 | AXTELL, ROBERT C | reporter.nih.gov |
| CLEC16A-driven regulation of astrocytes | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $549,256 | June 6, 2025 | May 31, 2030 | QUINTANA, FRANCISCO J. | reporter.nih.gov |
| Optimization and Characterization of Small Molecule GPR17 Antagonists for Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $547,846 | August 1, 2025 | July 31, 2027 | NARAYANAN, SANJU | reporter.nih.gov |
| Immunoregulation in CNS remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $538,904 | July 1, 2018 | August 31, 2025 | HUANG, JEFFREY K | reporter.nih.gov |
| An Enhanced Neurovascular Model with Scanning Conductance Imaging of Cell Junctions to Determine the Role of Matrix Metalloproteases in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $534,964 | July 1, 2025 | May 31, 2030 | SPENCE, DANA M | reporter.nih.gov |
| Identification of cellular heme transport receptors that regulate T cell function | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $531,300 | July 15, 2022 | June 30, 2024 | SOLT, LAURA A | reporter.nih.gov |
| Mechanisms of pathogenic microglial populations in CNS inflammation | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $521,839 | August 7, 2025 | July 31, 2030 | MENDIOLA, ANDREW S | reporter.nih.gov |
| Tolerogenic dual microparticle system for treatment of multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $520,957 | May 5, 2017 | April 30, 2022 | KESELOWSKY, BENJAMIN GEORGE | reporter.nih.gov |
| MRI predictors of disease and disability progression in African Americans with multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $518,697 | September 30, 2017 | January 31, 2024 | LUBLIN, FRED D | reporter.nih.gov |
| In vitro myelination assay modeling the environment of MS lesions for predictive discovery of remyelinating therapies. | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $506,083 | September 13, 2024 | August 31, 2025 | JAGIELSKA, ANNA | reporter.nih.gov |
| Spatial mapping of MS genetics on affected brain tissue | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $503,097 | March 1, 2022 | February 28, 2024 | CHITNIS, TANUJA | reporter.nih.gov |
| Biodegradable polymeric microparticles comprised of acetalated dextran induce immune tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $501,011 | November 15, 2024 | October 31, 2029 | AINSLIE, KRISTY M | reporter.nih.gov |
| Long non-coding RNA signatures to track treatment responses in multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $499,995 | September 1, 2019 | February 28, 2022 | SPURLOCK, CHARLES FLOYD | reporter.nih.gov |
| Distinct mast cell responses in male and female SJL mice underlie sex dimorphic EAE susceptibility | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $498,901 | July 14, 2017 | June 30, 2022 | BROWN, MELISSA A | reporter.nih.gov |
| Deconstructing interactions between diet, microbiome, and immunity to gain mechanistic insight into health and disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $498,000 | August 1, 2022 | April 30, 2026 | ALEXANDER, MARGARET ROSE | reporter.nih.gov |
| Development and Translation of D-glucose as an MRI Contrast Agent for Multiple Sclerosis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2022 | $497,696 | September 30, 2020 | June 30, 2024 | XU, XIANG | reporter.nih.gov |
| Real time imaging of immune cells and glutamate dynamics by PET and metabolic MRI | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $488,509 | September 21, 2023 | August 31, 2025 | GUGLIELMETTI, CAROLINE | reporter.nih.gov |
| Harnessing biomaterials to study the link between local lymph node function and systemic tolerance | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $485,482 | September 1, 2021 | December 31, 2022 | JEWELL, CHRISTOPHER M | reporter.nih.gov |
| Optimizing a Telehealth Behavioral Intervention for Fatigue in People with Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $484,704 | May 1, 2023 | April 30, 2028 | KNOWLES, LINDSEY MAJOR | reporter.nih.gov |
| Function of TCF-1 in antagonizing malignancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $484,000 | August 1, 2021 | July 31, 2023 | SUN, ZUOMING | reporter.nih.gov |
| Alu dsRNAs as adjuvants for influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $481,990 | April 7, 2022 | March 31, 2025 | AUNE, THOMAS M. | reporter.nih.gov |
| In Vivo Imaging of Cortical Glial Activation Using Advanced Diffusion Magnetic Resonance Imaging | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $479,639 | July 15, 2021 | December 31, 2024 | MAINERO, CATERINA | reporter.nih.gov |
| T Cell Epigenomic Drivers of Disease Flares in Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $476,575 | June 1, 2024 | April 30, 2027 | BUCKNER, JANE HOYT | reporter.nih.gov |
| Development and functions of tissue resident memory T cells during EAE | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $476,076 | February 1, 2022 | April 30, 2024 | BETTELLI, ESTELLE | reporter.nih.gov |
| OPC-X screen: Discovery of small molecule inhibitors to overcome extrinsic inhibition of remyelination. | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $472,500 | May 1, 2024 | May 31, 2027 | AKASSOGLOU, KATERINA | reporter.nih.gov |
| Exploring Akkermansia Genomic and Functional Diversity in Neurologic Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $472,026 | May 15, 2022 | October 30, 2024 | COX, LAURA MICHELLE | reporter.nih.gov |
| Modulation of pathogenic T cells in EAE | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $470,076 | November 13, 2023 | October 31, 2025 | BETTELLI, ESTELLE | reporter.nih.gov |
| Preclinical Evaluation of Anti-Fibrin Immunotherapy for Cerebral ALD: Leveraging a Novel Mouse Model to Guide Clinical Trial Design | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $469,622 | August 1, 2025 | July 31, 2027 | VAN HAREN, KEITH | reporter.nih.gov |
| Development of Advanced MRI for the Thoracolumbar Spinal Cord for Clinical Application | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $466,734 | July 8, 2020 | June 30, 2024 | O'GRADY, KRISTIN POOLE | reporter.nih.gov |
| A telehealth tDCS approach to decrease cannabis use: Towards reducing multiple sclerosis disability in multiple sclerosis | NIH | National Institute on Drug Abuse | 2022 to 2023 | $466,197 | March 15, 2022 | February 28, 2025 | CHARVET, LEIGH | reporter.nih.gov |
| Longitudinal Impact of Health and Lifestyle Behaviors on Cognition in Individuals with Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $466,184 | September 22, 2022 | August 31, 2027 | CHEN, MICHELLE H | reporter.nih.gov |
| Epigenomic regulation of oxidative stress-producing innate immunity in neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $462,836 | April 15, 2022 | November 30, 2026 | MENDIOLA, ANDREW S | reporter.nih.gov |
| The role of oligodendrocyte progenitor cells in neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $462,680 | April 1, 2021 | March 31, 2023 | GAULTIER, ALBAN P | reporter.nih.gov |
| Non invasive in vivo imaging of pathological fibrin deposition in the human brain | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $462,000 | February 15, 2022 | January 31, 2025 | MAINERO, CATERINA | reporter.nih.gov |
| Allograft inflammatory factor-1 and immune tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $462,000 | June 10, 2022 | August 31, 2024 | SIBINGA, NICHOLAS E | reporter.nih.gov |
| Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $461,751 | September 1, 2021 | October 11, 2021 | MOTL, ROBERT WAYNE | reporter.nih.gov |
| Intermittent Hypoxia Initiated Motor Plasticity in Individuals with Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2024 | $461,347 | September 4, 2023 | August 31, 2025 | SANDHU, MILAPJIT SINGH | reporter.nih.gov |
| Serological and cellular immune response to SARS-CoV-2 vaccination in pediatric multiple sclerosis on immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $460,866 | July 1, 2024 | May 31, 2027 | GOMBOLAY, GRACE YOONHEEKIM | reporter.nih.gov |
| Astrocyte-specific exosomes as a platform for biomarker discovery in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $460,625 | July 1, 2022 | June 30, 2025 | PITT, DAVID | reporter.nih.gov |
| OPC-X screen: Discovery of small molecule inhibitors to overcome extrinsic inhibition of remyelination. | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $458,325 | May 1, 2024 | April 30, 2025 | AKASSOGLOU, KATERINA | reporter.nih.gov |
| Developing Novel Neuroprotective Strategies for EAE/Optic Neuritis | NIH | National Eye Institute | 2021 | $455,432 | September 30, 2018 | June 30, 2023 | HU, YANG | reporter.nih.gov |
| Analyzing Oligodendrocytes-Derived Exosomes in Mouse Models of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $453,750 | June 1, 2022 | May 31, 2025 | DEGTEREV, ALEXEI | reporter.nih.gov |
| The Contribution of Central Nervous System Demyelination to Bladder Dysfuntion | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $451,000 | September 30, 2021 | March 31, 2024 | CROCKER, STEPHEN J | reporter.nih.gov |
| Detailed molecular and structural characterization of the meninges: an approach combining proteomics and Imaging Mass Cytometry | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $451,000 | February 1, 2022 | January 31, 2025 | PACHTER, JOEL S | reporter.nih.gov |
| A Non-Viral Genetic Vaccine for Prevention and Treatment of Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $450,313 | March 17, 2021 | February 29, 2024 | GREEN, JORDAN | reporter.nih.gov |
| Understanding the role of aromatic amino acid derived metabolic toxins in neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $450,313 | March 1, 2022 | February 29, 2024 | BHARGAVA, PAVAN | reporter.nih.gov |
| Theranostic Metabolic Imaging of Oxidative Stress in Multiple Sclerosis. | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $444,125 | January 23, 2023 | December 31, 2024 | CHAUMEIL, MYRIAM MARIANNE | reporter.nih.gov |
| The genetic basis of progression in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $442,759 | September 30, 2017 | December 31, 2022 | BARANZINI, SERGIO E | reporter.nih.gov |
| The effects of BTNL2 on experimental autoimmune encephalomyelitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $442,750 | March 4, 2021 | February 28, 2025 | LAI, LAIJUN | reporter.nih.gov |
| Characterizing the oxysterol, 20-hydroxycholesterol, as a mediator of remyelination in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $442,750 | July 1, 2021 | December 31, 2024 | GREGORY, SIMON G | reporter.nih.gov |
| Molecular correlates of sub-regional thalamic degeneration in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $442,750 | February 1, 2022 | January 31, 2025 | DUTTA, RANJAN | reporter.nih.gov |
| Investigation of discrete neurodegenerative changes of the in vivo multiple sclerosis spinal cord using 7T MRI | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $442,750 | July 18, 2024 | June 30, 2026 | MAHAJAN, KEDAR | reporter.nih.gov |
| Development of novel PD1 agonist therapeutic strategies for multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $441,690 | January 1, 2023 | December 31, 2024 | GOPAL, MURUGAIYAN | reporter.nih.gov |
| An electro-mechanical mechanism of spike propagation in myelinated axons | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $440,687 | April 1, 2021 | September 30, 2023 | KRAMER, RICHARD H | reporter.nih.gov |
| Discovering new therapies to promote myelin repair | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $440,030 | August 1, 2021 | January 31, 2024 | GAULTIER, ALBAN P | reporter.nih.gov |
| MICRORNA CONTROL OF INFLAMMATORY AND REGULATORY T CELLS IN CENTRAL NERVOUS SYSTEM AUTOIMMUNITY | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $439,410 | February 1, 2017 | January 31, 2023 | GOPAL, MURUGAIYAN | reporter.nih.gov |
| Role of a gut microbiota metabolite indole lactate in myelin repair | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $439,027 | July 8, 2025 | April 30, 2030 | BHARGAVA, PAVAN | reporter.nih.gov |
| Regulation of the Microglial Neuroimmune Response by Long Non-Coding RNAs | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $436,468 | July 14, 2022 | June 30, 2025 | SHIBATA, ANNEMARIE | reporter.nih.gov |
| AhR ligands in epigenetic dysregulation of T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $435,108 | February 10, 2017 | January 31, 2023 | NAGARKATTI, MITZI | reporter.nih.gov |
| Development of Drugs that Modify CNS Innate Immunity for the Treatment of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $434,860 | April 15, 2022 | August 31, 2026 | QUINTANA, FRANCISCO J. | reporter.nih.gov |
| Immunologic Characterization of CSF microglia in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $433,125 | April 1, 2021 | March 31, 2024 | WU, GREGORY | reporter.nih.gov |
| Therapy for long-COVID in a preclinical model | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $433,125 | July 11, 2024 | May 31, 2027 | KAUFMAN, DANIEL | reporter.nih.gov |
| How Does 3' UTR Secondary Structure Program mRNA Transport in Myelination? | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $432,982 | August 1, 2021 | January 31, 2024 | ZUCHERO, JOHN B | reporter.nih.gov |
| Effect of dysbiotic gut microbiota on the transport of short-chain fatty acids: Relevance to autoimmune disorders | NIH | National Center for Complementary & Integrative Health | 2024 | $431,750 | September 16, 2024 | August 31, 2026 | ITO, KOUICHI | reporter.nih.gov |
| Immunoregulatory effect of microparticle delivered STING agonist in the control of experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $430,932 | April 15, 2021 | March 31, 2024 | MARKOVIC-PLESE, SILVA | reporter.nih.gov |
| Viral impact on autoimmune T cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $430,931 | June 18, 2021 | May 31, 2023 | GAFFEN, SARAH L | reporter.nih.gov |
| Longitudinal Measurement of Neurodegeneration in two Murine Models of Multiple Sclerosis: A Clinical and Histopathologic Validation Study | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $430,872 | January 15, 2021 | December 31, 2024 | GILLI, FRANCESCA | reporter.nih.gov |
| B cell-targeted CAR-T treatment of CNS Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $430,625 | August 5, 2022 | July 31, 2024 | WU, GREGORY | reporter.nih.gov |
| The Mechanism of Gray Matter Atrophy in Experimental Autoimmune Encephalomyelitis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $429,000 | April 1, 2021 | September 30, 2023 | MACKENZIE-GRAHAM, ALLAN JAMES | reporter.nih.gov |
| Detection and evolution of diffusely abnormal white matter in multiple sclerosis: a deep learning approach | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $429,000 | April 1, 2021 | September 30, 2024 | HASAN, KHADER M | reporter.nih.gov |
| Analysis of mouse models of premature glial senescence | NIH | National Institute on Aging | 2022 to 2023 | $429,000 | February 1, 2022 | January 31, 2024 | HUANG, JEFFREY K | reporter.nih.gov |
| Regulation of pathogenic T cells in EAE | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $428,750 | December 1, 2016 | November 30, 2022 | BETTELLI, ESTELLE | reporter.nih.gov |
| Gamma herpesvirus impact on required B cell:CD4 T interactions in a B cell-dependent, antibody-independent mouse model of multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $427,627 | July 1, 2025 | June 30, 2027 | BOYDEN, ALEXANDER | reporter.nih.gov |
| Utilizing CNS tissue derived extracellular vesicles to identify biomarkers of remyelination and demyelination | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $427,104 | September 23, 2025 | August 31, 2027 | BHARGAVA, PAVAN | reporter.nih.gov |
| The role of sulfatide in myelin stability | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $426,938 | September 30, 2021 | August 31, 2024 | DUPREE, JEFFREY L. | reporter.nih.gov |
| GLT-1/EAAT2 signaling as a novel player in myelin repair | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $426,938 | July 9, 2024 | June 30, 2026 | FUSS, BABETTE | reporter.nih.gov |
| Rescuing myelination in viral infections of the juvenile brain | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $426,057 | September 20, 2024 | August 31, 2027 | O'DONNELL, LAUREN ALENE | reporter.nih.gov |
| Macromolecular Imaging of Gray and White Matter Pathology in Multiple Sclerosis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $425,691 | September 30, 2018 | June 30, 2024 | SAMSONOV, ALEXEY | reporter.nih.gov |
| Role of B cell interactions in CNS autoimmune demyelination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $424,875 | March 10, 2021 | February 29, 2024 | BOYDEN, ALEXANDER | reporter.nih.gov |
| Chronic effects of different THC:CBD ratios on executive function and emotional processing in people with multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $424,875 | December 1, 2021 | November 30, 2024 | GANDER, PHILLIP EVAN | reporter.nih.gov |
| Identification of eye-homing peptides and their use for targeted liposomal drug delivery in posterior uveitis | NIH | National Eye Institute | 2022 to 2023 | $424,875 | May 1, 2022 | April 30, 2026 | MOUDGIL, KAMAL D | reporter.nih.gov |
| In vivo tracking of innate immune activation and therapeutic response in MS mouse models using [18F]OP-801 | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $424,234 | May 16, 2025 | April 30, 2027 | JAMES, MICHELLE LOUISE | reporter.nih.gov |
| PD-1 BiKE: Targeting and Depleting PD-1 Positive Cells for Autoimmune Disease Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $423,500 | July 22, 2025 | June 30, 2027 | CHEN, MINGNAN | reporter.nih.gov |
| A 3-In-One Design of CAR Tregs for Robust Immunotolerance | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $423,500 | July 1, 2025 | June 30, 2027 | CHEN, MINGNAN | reporter.nih.gov |
| Pathogenic B cell and T helper cell interactions in Neuromyelitis Optica | NIH | National Eye Institute | 2021 | $423,162 | September 30, 2017 | June 30, 2023 | AXTELL, ROBERT C | reporter.nih.gov |
| Use of use of dimethyl fumarate for targeting autoimmunity in type 1 diabetes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $422,125 | September 24, 2021 | August 31, 2024 | VENDRAME, FRANCESCO | reporter.nih.gov |
| Targeting cholesterol homeostasis for therapy of demyelinating eye disease | NIH | National Eye Institute | 2025 | $422,125 | August 1, 2025 | July 31, 2027 | BRAMBILLA, ROBERTA | reporter.nih.gov |
| Investigating the role of cerebral perfusion in demyelination and repair in multiple sclerosis with MRI | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $421,988 | June 1, 2022 | May 31, 2025 | STOKES, ASHLEY M | reporter.nih.gov |
| Therapeutic potential of affinity enhanced pMHCII-4E reagents | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $420,438 | November 17, 2023 | October 31, 2026 | DILEEPAN, THAMOTHARAMPILLAI | reporter.nih.gov |
| Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $420,111 | September 30, 2018 | August 31, 2024 | GAUTHIER, SUSAN A | reporter.nih.gov |
| Investigation of AhR Ligands on FcGamma Receptor Signaling: Consequences of Antibody Suppression | NIH | National Institute of Environmental Health Sciences | 2022 | $419,864 | September 30, 2017 | July 31, 2025 | KAPLAN, BARBARA LEE-FAUBERT | reporter.nih.gov |
| Therapeutic Mechanisms of Farnesol in Modulating Gut Dysbiosis and Neuroinflammation in Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $418,493 | June 20, 2025 | May 31, 2028 | OCHOA-REPARAZ, JAVIER | reporter.nih.gov |
| IL-1R1, MMP-9, and EAE | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $418,251 | January 21, 2022 | December 31, 2023 | QUAN, NING | reporter.nih.gov |
| Regulation of CD4+ T cell-mediated Demyelination Following Oligo Ablation | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $417,645 | July 15, 2017 | June 30, 2022 | MILLER, STEPHEN D | reporter.nih.gov |
| Optimizing Treatment Decisions for Acute Demyelinating Optic Neuritis | NIH | National Eye Institute | 2021 to 2022 | $415,218 | September 30, 2018 | August 31, 2023 | DE LOTT, LINDSEY BLAKE | reporter.nih.gov |
| Regulation of CNS Autoimmunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $412,750 | February 2, 2017 | January 31, 2023 | QUINTANA, FRANCISCO J. | reporter.nih.gov |
| Combating chronic neuroinflammatory disorders by targeting NAC1 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $412,584 | June 1, 2022 | May 31, 2025 | SONG, JIANXUN JIM | reporter.nih.gov |
| Backward Walking as a Novel Fall Prediction Tool for Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $412,130 | August 1, 2022 | July 31, 2025 | FRITZ, NORA E. | reporter.nih.gov |
| Endothelin signaling in neural stem cell homeostasis and remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $411,734 | August 6, 2025 | July 31, 2030 | ADAMS, KATRINA L | reporter.nih.gov |
| Altered CD4+ T cell function in relation to the AHI1 MS locus | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $405,000 | April 1, 2017 | March 31, 2023 | ELYAMAN, WASSIM | reporter.nih.gov |
| The Role of TRPV4 in central nervous system immunity and disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $401,701 | September 1, 2018 | August 31, 2022 | WU, GREGORY | reporter.nih.gov |
| Investigating changes in myelin lipid composition during relapsing-remitting neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $400,258 | March 15, 2024 | February 28, 2027 | FORSTHUBER, THOMAS G. | reporter.nih.gov |
| Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $399,107 | September 15, 2021 | August 31, 2023 | TRAN, HIEP T | reporter.nih.gov |
| Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 | $395,119 | September 18, 2023 | November 30, 2024 | SCHULTZ, KENNETH | reporter.nih.gov |
| Mechanisms of GM-CSF effect in CNS autoimmune demyelination | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $390,000 | December 15, 2016 | November 30, 2023 | ROSTAMI, A.M. | reporter.nih.gov |
| Post-translational modifications in RORgt-dependent immune cell functions | NIH | National Institute of General Medical Sciences | 2021 | $388,720 | September 1, 2017 | May 31, 2022 | HUANG, WENDY JIA MEN | reporter.nih.gov |
| Astrocytic control of lymphocyte migration and differentiation in CNS inflammatory lesions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $386,640 | September 1, 2018 | August 31, 2023 | HORNG, SAM H | reporter.nih.gov |
| In vivo modeling of autoantibody-induced optic neuritis | NIH | National Eye Institute | 2021 to 2022 | $386,015 | July 1, 2021 | June 30, 2024 | GRAMLICH, OLIVER W | reporter.nih.gov |
| Defining the Role of Epstein-Barr Virus in Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $385,992 | April 1, 2024 | March 31, 2029 | SATTARNEZHAD OSKOUEI, NEDA | reporter.nih.gov |
| Objective Mobile diagnostics for Optic Neuropathies | NIH | National Eye Institute | 2025 | $375,940 | September 15, 2025 | August 31, 2027 | VERSEK, CRAIG | reporter.nih.gov |
| Capacity building for timely diagnosis of Multiple Sclerosis and prevention of disability | NIH | Fogarty International Center | 2025 | $375,319 | September 15, 2025 | August 31, 2027 | AMEZCUA, LILYANA | reporter.nih.gov |
| Thalamic MRI, histopathologic, and clinical correlations in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $368,522 | September 15, 2018 | June 30, 2024 | MAHAJAN, KEDAR | reporter.nih.gov |
| Regulation of CNS leukocyte extravasation | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $367,158 | June 15, 2017 | April 30, 2024 | PACHTER, JOEL S | reporter.nih.gov |
| Circadian Rhythms and Sleep, Structural Neuroimaging and Depression in People with Multiple Sclerosis | NIH | National Institute of Mental Health | 2021 to 2022 | $358,566 | September 10, 2019 | August 31, 2024 | FITZGERALD, KATHRYN C. | reporter.nih.gov |
| Arginase-1 and iNOS expressing CNS myeloid cell subsets in EAE and MS | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $357,525 | August 1, 2019 | July 31, 2022 | SEGAL, BENJAMIN M | reporter.nih.gov |
| Inflammation mediated evolving changes in synapse structural integrity and dynamics in vivo in a mouse model of multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $346,896 | July 15, 2018 | October 31, 2023 | GILLANI, REBECCA LYNN | reporter.nih.gov |
| Vasculature provides the substrate for oligodendrocyte progenitor migration in development and disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $346,719 | March 15, 2017 | February 28, 2023 | FANCY, STEPHEN PHILIP JAMES | reporter.nih.gov |
| Detection, characterization and treatment of chronic microglial inflammation in established MS lesions | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $346,631 | August 1, 2017 | May 31, 2022 | PITT, DAVID | reporter.nih.gov |
| Intermittent Fasting-induced Gut Microbiome Modulation of CNS Autoimmunity | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $346,172 | July 15, 2017 | February 28, 2023 | ZHOU, YANJIAO | reporter.nih.gov |
| Interactions Between Host Genetics and the Gut Microbiome in CNS Autoimmunity | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $341,250 | March 15, 2017 | January 31, 2024 | KREMENTSOV, DIMITRY N | reporter.nih.gov |
| Ursolic acid: a novel oral therapy for chronic stage of MS/EAE by both immunomodulation and neural repair | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $341,250 | June 1, 2017 | April 30, 2023 | ZHANG, GUANG-XIAN | reporter.nih.gov |
| Homeostatic regulation of NG2 cell dynamics | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $337,235 | June 15, 2011 | July 31, 2023 | NISHIYAMA, AKIKO | reporter.nih.gov |
| Deletion of Mitochondrial Anchoring Protects Late Phase Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $334,688 | April 1, 2017 | March 31, 2023 | CHIU, SHING YAN | reporter.nih.gov |
| 2D kinetics of antigen recognition in the CNS | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $333,594 | June 1, 2010 | May 31, 2023 | EVAVOLD, BRIAN D | reporter.nih.gov |
| Improving Diagnosis of Multiple Sclerosis Through the Integration of Novel Imaging and Laboratory Biomarkers | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $332,575 | January 1, 2019 | December 31, 2024 | SOLOMON, ANDREW J | reporter.nih.gov |
| Promotion of Exercise for Multiple Sclerosis through Physical Therapy (PromPT) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $328,524 | August 1, 2024 | July 31, 2026 | KINNETT-HOPKINS, DOMINIQUE | reporter.nih.gov |
| Role of microglia in MHV-induced demyelination | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $326,546 | September 1, 1997 | January 31, 2023 | PERLMAN, STANLEY | reporter.nih.gov |
| Development of antisense oligonucleotides that enhance sIL7R as novel cancer immunotherapy | NIH | National Cancer Institute | 2021 | $324,675 | September 1, 2021 | August 31, 2023 | GALARZA-MUNOZ, GADDIEL | reporter.nih.gov |
| Associations of biological aging with outcomes and immune dysregulation in multiple sclerosis | NIH | National Institute on Aging | 2024 to 2025 | $323,342 | July 1, 2024 | June 30, 2029 | ZHANG, YINAN | reporter.nih.gov |
| Retrospective Magnetic Resonance Image Harmonization for Robust Federated Learning | NIH | National Library of Medicine | 2025 | $320,622 | July 28, 2025 | May 31, 2029 | PHAM, DZUNG L | reporter.nih.gov |
| Markers of Biological Aging in Multiple Sclerosis | NIH | National Institute on Aging | 2022 to 2023 | $315,000 | September 1, 2022 | May 31, 2025 | ZHANG, YINAN | reporter.nih.gov |
| Vermont Center for Immunobiology/Infectious Diseases (VCIID) | NIH | National Institute of General Medical Sciences | 2021 | $308,903 | August 1, 2020 | July 31, 2022 | BUDD, RALPH C | reporter.nih.gov |
| Stem-like T cells as bioindicators and orchestrators of the disease process in MS and animal models | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $305,000 | August 12, 2024 | July 31, 2025 | HAWIGER, DANIEL | reporter.nih.gov |
| Nanoimmunotherapy for chronic immune-mediated diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | July 14, 2022 | June 30, 2023 | HORWITZ, DAVID A | reporter.nih.gov |
| Immune Checkpoint-Engineered oligodendrocytes as treatment for multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $300,000 | September 10, 2025 | August 31, 2026 | WANG, ANDREW ZHUANG | reporter.nih.gov |
| Elucidating symptoms clusters in multiple sclerosis using patient reported outcomes and unsupervised machine learning | NIH | National Institute of Nursing Research | 2021 to 2022 | $297,252 | August 24, 2021 | June 30, 2023 | BRIGGS, FARREN B. S. | reporter.nih.gov |
| Targeting Cholesterol Homeostasis to maintain vision in MS-like optic neuritis | NIH | National Eye Institute | 2025 | $295,245 | August 1, 2023 | March 31, 2028 | GRAMLICH, OLIVER W | reporter.nih.gov |
| Spatiotemporal tuning of myelin antigens and rapamycin for enhanced antigen-specific immune tolerance in multiple sclerosis. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $295,051 | September 1, 2021 | June 23, 2023 | CATINO, JOSEPH J | reporter.nih.gov |
| Novel immunotherapy against MOG antibody disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $287,733 | July 15, 2022 | July 15, 2023 | BARRETT, GREG | reporter.nih.gov |
| Barriers to Healthcare and Cardiovascular Risk Influences on Accelerated Brain Aging and Disability in Hispanic Persons with Multiple Sclerosis | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2024 | $281,618 | September 23, 2023 | March 31, 2028 | ROMÁN, CRISTINA A. F. | reporter.nih.gov |
| Feasibility and Initial Efficacy of a Wheelchair Exercise-Training Intervention for Persons with Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2024 | $272,884 | October 1, 2023 | October 31, 2025 | GEE, STEPHANIE SILVEIRA | reporter.nih.gov |
| Prioritizing and Characterizing T Cell-Relevant Genetic Variants Associated with Autoimmune Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $270,000 | December 18, 2020 | November 30, 2022 | RAY, JOHN PHILIP | reporter.nih.gov |
| STAT5 tetramerization in autoimmune-mediated neuroinflammation | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $266,000 | June 7, 2022 | December 31, 2023 | WAN, EDWIN CHI KEUNG | reporter.nih.gov |
| Oral N-Acetylglucosamine as Anti-Neuroinflammatory Add-on therapy for Multiple Sclerosis (NANA-MS) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $263,892 | August 1, 2025 | July 31, 2027 | DEMETRIOU, MICHAEL | reporter.nih.gov |
| How myelin regulates vestibular circuit function and balance behaviors | NIH | National Institute on Deafness and Other Communication Disorders | 2024 to 2025 | $258,336 | March 1, 2024 | March 31, 2026 | AUER, FRANZISKA | reporter.nih.gov |
| Patient Oriented Research and Mentoring in Multidisciplinary Chronic Pain Treatments | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $255,917 | September 6, 2024 | August 31, 2029 | KRATZ, ANNA LOUISE | reporter.nih.gov |
| Translating Genetic Risk Factors to Therapies: From Big Data to Druggable Targets | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $253,497 | July 1, 2021 | June 30, 2026 | SHAW, BENJAMIN C. | reporter.nih.gov |
| Ethnicity-Associated, Differential CNS Demyelinating Autoimmune Disease Severity: Reconciling Identity, Ancestry and Neurotoxic Antibody Response | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $252,450 | July 1, 2021 | June 30, 2024 | TELESFORD, KIEL | reporter.nih.gov |
| Investigating the Impact of Cognition on Capacity in Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $252,350 | September 12, 2018 | February 29, 2024 | GERSTENECKER, ADAM TYLER | reporter.nih.gov |
| Transcriptional regulation of oligodendroglial differentiation | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $251,370 | August 1, 2024 | June 30, 2026 | ROJO CAPITANIO, DANIELA | reporter.nih.gov |
| Long non-coding RNA signatures to distinguish relapsing-remitting multiple sclerosis from primary progressive and secondary progressive multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $248,284 | September 2, 2022 | August 31, 2023 | SPURLOCK, CHARLES FLOYD | reporter.nih.gov |
| Quantitative myelin mapping in vivo for clinical and pre-clinical MRI | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $244,055 | September 30, 2018 | July 31, 2023 | YARNYKH, VASILY L. | reporter.nih.gov |
| Epigenomic regulation of oxidative stress-producing innate immunity in neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $241,728 | April 15, 2022 | September 30, 2023 | MENDIOLA, ANDREW S | reporter.nih.gov |
| High-resolution mapping of the human brainstem during continence and micturition: noninvasive in vivo 7 Tesla fMRI study | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2022 | $241,577 | January 18, 2021 | December 31, 2023 | KHAVARI, ROSE | reporter.nih.gov |
| Defining Epstein-Barr virus reservoirs and EBV-regulated gene expression in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $237,476 | August 1, 2025 | July 31, 2027 | LUFTIG, MICAH ALAN | reporter.nih.gov |
| University of Pennsylvania Clinical Autoimmunity Center of Excellence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $236,670 | May 1, 2019 | April 30, 2024 | PAYNE, AIMEE S | reporter.nih.gov |
| Imaging remyelination in multiple sclerosis using metabolic and ultra-short echo time MRI | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $233,250 | December 20, 2024 | November 30, 2026 | GUGLIELMETTI, CAROLINE | reporter.nih.gov |
| Toward a CRISPR-AAV Gene Therapy Targeting a Mitochondrial Anchor to Treat Progressive Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $232,813 | December 1, 2019 | May 31, 2023 | CHIU, SHING YAN | reporter.nih.gov |
| Friend or Foe? The AMPK Signaling Pathway During Developmental Myelination | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $232,524 | April 1, 2025 | March 31, 2027 | COLOGNATO, HOLLY A | reporter.nih.gov |
| Theiler's virus RNA in exosomes secreted by infected microglia | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $232,000 | March 12, 2020 | February 29, 2024 | OLSON, JULIE K | reporter.nih.gov |
| Immune Regulation of the Blood-Brain Barrier | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $230,580 | December 1, 2024 | November 30, 2029 | WILCOX, DOUGLAS ROBERT | reporter.nih.gov |
| Mechanisms of Claudin-5 Regulation during Neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $224,930 | August 1, 2025 | February 28, 2026 | BEARD, RICHARD SCOTT | reporter.nih.gov |
| Molecular Mechanisms of Multiple Sclerosis Disease Severity In African Americans | NIH | National Institute on Minority Health and Health Disparities | 2021 | $222,750 | August 24, 2020 | April 30, 2024 | RAMAN, CHANDER | reporter.nih.gov |
| Fast High-Resolution Microstructure Diffusion MRI Exploiting Data Redundancy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $222,238 | August 1, 2024 | July 31, 2026 | COELHO, SANTIAGO | reporter.nih.gov |
| The Role of T cells in children with anti-NMDA Receptor Encephalitis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $219,645 | August 15, 2025 | July 31, 2030 | GOMBOLAY, GRACE YOONHEEKIM | reporter.nih.gov |
| Optimization of Small Molecule GPR17 Antagonists for Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $217,601 | March 15, 2021 | February 29, 2024 | NARAYANAN, SANJU | reporter.nih.gov |
| Stress Biology and Psychosocial stressors as mechanisms for Racial Health Disparities in Neural and Clinical Impairments of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $217,189 | July 1, 2022 | July 31, 2027 | MOODY, SHANNIN NICOLE | reporter.nih.gov |
| Mechanisms of suppression of effector T cells in EAE | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $213,875 | January 21, 2020 | December 31, 2022 | BETTELLI, ESTELLE | reporter.nih.gov |
| Determining Enhanced Inflammatory B cell Function in African Americans with MS | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $211,875 | February 3, 2020 | January 31, 2022 | VARTANIAN, TIMOTHY | reporter.nih.gov |
| Identification of complex cellular phenotypes and their interactions in MS lesions | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $209,375 | January 14, 2020 | December 31, 2022 | PITT, DAVID | reporter.nih.gov |
| Fast and robust quantitative MRI with tissue-susceptibility mapping of the human brain | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $206,882 | August 1, 2024 | July 31, 2026 | WANG, NAN | reporter.nih.gov |
| Oligodendroglial Intrinsic Ring Finger Protein family members are injury specific, but not developmental, regulators of oligodendrocyte maturation | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $201,875 | September 1, 2020 | August 31, 2022 | FANCY, STEPHEN PHILIP JAMES | reporter.nih.gov |
| Dissecting the Heterogeneous Molecular Mechanisms Underlying Multiple Sclerosis Progression | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $198,928 | August 1, 2025 | July 31, 2030 | ABDELHAK, AHMED | reporter.nih.gov |
| Regulation of Neuromyelitis Optica via Tolerance Induced by PLG Nanoparticles Encapsulating Aquaporin 4 Epitopes | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $198,333 | January 24, 2020 | December 31, 2021 | MILLER, STEPHEN D | reporter.nih.gov |
| Autoimmunity to Axoglial Apparatus Proteins in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $196,020 | July 1, 2019 | July 31, 2021 | PATTERSON, KRISTINA RAE | reporter.nih.gov |
| Regulation of node of Ranvier formation and maintenance by astrocytes | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $192,734 | August 1, 2021 | May 31, 2024 | CALL, CODY LEE | reporter.nih.gov |
| Just-In-Time Fall Prevention: Development of an mHealth Intervention for Persons with Multiple Sclerosis | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $190,266 | September 6, 2019 | August 31, 2023 | MCGINNIS, RYAN S. | reporter.nih.gov |
| Real time imaging of immune cells and glutamate dynamics by PET and metabolic MRI | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $187,784 | August 8, 2022 | August 31, 2023 | GUGLIELMETTI, CAROLINE | reporter.nih.gov |
| Ethnicity-Associated, Differential CNS Demyelinating Autoimmune Disease Severity: Reconciling Identity, Ancestry and Neurotoxic Antibody Response | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $186,624 | July 1, 2021 | May 31, 2028 | TELESFORD, KIEL | reporter.nih.gov |
| Deconstructing interactions between diet, microbiome, and immunity to gain mechanistic insight into health and disease | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $176,513 | August 1, 2022 | October 31, 2023 | ALEXANDER, MARGARET ROSE | reporter.nih.gov |
| Development of clinically translatable MRI methodologies for the thoracic spinal cord | NIH | National Center for Advancing Translational Sciences | 2023 | $175,000 | September 1, 2023 | August 31, 2025 | O'GRADY, KRISTIN POOLE | reporter.nih.gov |
| Assessing Cognitive Overload in People with Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $173,232 | August 1, 2025 | July 31, 2030 | NYLANDER, ALYSSA NICOLE | reporter.nih.gov |
| Interferon-gamma mediates neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy (MSA) | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $172,380 | July 20, 2023 | June 30, 2028 | CORBIN-STEIN, NICOLE | reporter.nih.gov |
| The Educational Impact of Childhood-Onset Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $166,312 | June 13, 2019 | May 31, 2023 | VARGAS, WENDY | reporter.nih.gov |
| Bright Light Therapy for Sleep Disturbance in Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 | $163,750 | March 19, 2020 | December 31, 2023 | FITZGERALD, KATHRYN C. | reporter.nih.gov |
| Johns Hopkins Autoimmunity Center of Excellence | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $163,750 | August 1, 2024 | July 31, 2029 | PAIK, JULIE JISUN | reporter.nih.gov |
| Imaging innate and adaptive immune response in MS using using [18F]F-AraG PET and hyperpolarized 13C MRSI | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $161,500 | June 1, 2020 | May 31, 2024 | CHAUMEIL, MYRIAM MARIANNE | reporter.nih.gov |
| The role of ion channels and transporters in B cell function | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $158,420 | July 17, 2022 | July 16, 2025 | TAO, ANTHONY | reporter.nih.gov |
| Using quantitative gradient echo MRI to distinguish MOG antibody disorder from multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $157,500 | April 1, 2021 | September 30, 2023 | CROSS, DOROTHY ANNE | reporter.nih.gov |
| Compensatory mechanisms of estrogen mediated protection from EAE in IL-10 KO mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $157,500 | September 14, 2020 | August 31, 2023 | OFFNER, HALINA | reporter.nih.gov |
| Impact of pathogenic MS patient-derived IgG on oligodendrocytes: bystanders or participants in remyelination failure? | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $157,407 | September 1, 2021 | December 31, 2023 | LAPATO, ANDREW S | reporter.nih.gov |
| Development of a conditional ataxin-1 knockout mouse line | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $151,000 | February 15, 2023 | January 31, 2026 | DIDONNA, ALESSANDRO | reporter.nih.gov |
| Walking Inefficiency in Multiple Sclerosis: Influence of Vascular Dysfunction | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $149,348 | June 1, 2024 | May 31, 2026 | JENG, BRENDA | reporter.nih.gov |
| How Do Astrocytes Participate in Demyelination and Myelin Repair | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $145,152 | September 1, 2021 | October 30, 2024 | COLÓN ORTIZ, CRYSTAL K | reporter.nih.gov |
| Investigating the role of cannabinoid receptors in oligodendrocyte development | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $143,807 | February 1, 2023 | December 31, 2025 | MIRAMONTES, TANIA G | reporter.nih.gov |
| Microglia and S1PR1 Signaling in Multiple Sclerosis Associated Neuropathic Pain | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $143,420 | September 1, 2022 | August 31, 2025 | LAMERAND, SYDNEY | reporter.nih.gov |
| Investigating the link between REV-ERB and HIF-1a in Th17 cell function | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $142,622 | July 11, 2023 | June 30, 2025 | GRIFFETT, KRISTINE | reporter.nih.gov |
| The Role of an Effort-Reward Imbalance in Cognitive Fatigue | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $136,402 | April 1, 2021 | March 31, 2024 | ERANI, FARESHTE | reporter.nih.gov |
| Global and Local Genetic Ancestry Impacts on Differential Outcome of Systemic Lupus Erythematosus and Multiple Sclerosis | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $129,976 | September 1, 2021 | August 31, 2024 | SOLOMON, OLIVIA | reporter.nih.gov |
| A novel role for cell cycle regulators in oligodendrogenesis and myelination | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $126,122 | August 7, 2025 | July 31, 2027 | CALL, CODY LEE | reporter.nih.gov |
| Engineered extracellular vesicles as a targeted drug delivery system for multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $108,872 | December 1, 2021 | June 30, 2024 | MIZENKO, RACHEL REGINA | reporter.nih.gov |
| Developing controlled release immune complexes to treat multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $104,982 | March 5, 2023 | July 31, 2024 | ACKUN-FARMMER, MARIAN ADRIANA | reporter.nih.gov |
| SUPRASPINAL TARGETS IN NEUROGENIC VOIDING DYSFUNCTION | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $100,210 | August 17, 2018 | July 31, 2022 | KHAVARI, ROSE | reporter.nih.gov |
| Inhibition of MIF nuclease-mediated parthanatos prevents neuron and oligodendrocyte death in the context of multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $98,512 | December 4, 2023 | June 3, 2026 | MACE, JACKSON | reporter.nih.gov |
| Investigating Fear of Falling in Multiple Sclerosis: An Interplay of Neural, Motor, Cognitive, and Psychological Factors | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $97,376 | August 1, 2024 | July 31, 2026 | TAKLA, TAYLOR | reporter.nih.gov |
| Role of GPNMB Signaling in Remyelination by Oligodendrocyte Progenitor Cells | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $95,349 | April 1, 2022 | June 30, 2023 | SAMANTA, JAYSHREE | reporter.nih.gov |
| Molecular Control of Astrocytes in CNS Inflammation | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $94,500 | August 15, 2020 | July 30, 2022 | WHEELER, MICHAEL ALEX | reporter.nih.gov |
| Identifying novel targets and mechanistic role of 8,9 unsaturated sterol accumulation on enhancement of oligodendrocyte formation | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $93,635 | December 6, 2021 | December 1, 2023 | ATALA PLESHINGER, MATTHEW | reporter.nih.gov |
| Immulogical Niches and Non-invasive Biosensors for Autoimmune Monitoring | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 | $91,800 | September 1, 2020 | September 14, 2022 | MORRIS, AARON HARVEY | reporter.nih.gov |
| Developing Remyelination Strategies for Demyelinating Optic Neuropathies Using Human Pluripotent Stem Cells | NIH | National Eye Institute | 2021 | $88,947 | May 1, 2019 | December 31, 2021 | CHAMLING, XITIZ | reporter.nih.gov |
| Precision Monitoring of Multiple Sclerosis with Mobile Devices: A Transformative Approach | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $85,378 | August 1, 2024 | July 31, 2026 | HITTLE, MICHAEL | reporter.nih.gov |
| Role of NK cell subsets in an animal model of relapsing-remittingmultiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $81,000 | August 1, 2025 | July 31, 2027 | IFERGAN, IGAL | reporter.nih.gov |
| Peripheral mechanisms of central neuropathic pain in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $80,753 | August 15, 2021 | September 30, 2022 | NGUYEN, KAYLA LEE | reporter.nih.gov |
| Novel knockout models to analyze CD38 function | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $78,000 | June 3, 2020 | July 31, 2023 | GUERAU-DE-ARELLANO, MIREIA | reporter.nih.gov |
| Exploring biomarkers of sex-based disparities in relapsing multiple sclerosis | NIH | National Institute of Nursing Research | 2022 to 2023 | $77,422 | May 31, 2022 | May 30, 2024 | BUXHOEVEDEN, STEPHANIE KATE | reporter.nih.gov |
| Neuronal activity-dependent intracellular calcium signaling regulates oligodendrocyte maturation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $77,371 | July 1, 2021 | August 31, 2023 | THORNTON, MICHAEL A | reporter.nih.gov |
| Cystatin F expression on microglia is critical for constraining demyelination following viral infection of the central nervous system | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $75,052 | September 1, 2025 | August 31, 2027 | MURRAY, KAITLIN | reporter.nih.gov |
| Investigating the Role of Endosomal Toll-Like Receptors in Remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $73,302 | July 1, 2024 | June 30, 2026 | STILLMAN, JACOB MAXWELL | reporter.nih.gov |
| The Role of Myeloid Cell-Specific Ten-Eleven Translocase 2 (TET2) in Regulation of Neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $70,498 | April 1, 2021 | December 31, 2022 | GARDNER, ASHLEY MUNIE | reporter.nih.gov |
| Examining Microglia Reactivation in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $69,810 | August 1, 2024 | July 31, 2026 | BARCLAY, KIA | reporter.nih.gov |
| Establishing the Role of Genetic Variation in Vitamin D Regulated Gene Expression in MS Pathogenesis and Severity | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $67,730 | April 1, 2020 | July 31, 2022 | ADAMS, CAMERON | reporter.nih.gov |
| Developing new strategies to promote axon myelination for vision restoration | NIH | National Eye Institute | 2021 | $64,875 | May 1, 2021 | April 20, 2022 | SUTER, TRACEY AMELIA CLAIRE SAMPATH | reporter.nih.gov |
| Defining the role of B cells in modulating CNS inflammation in multiple sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $62,416 | July 1, 2020 | November 30, 2022 | AHN, JULIE J | reporter.nih.gov |
| Obesity Rehabilitation for Improving Walking Efficiency in Neurological Disease | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $59,834 | February 4, 2021 | May 1, 2022 | JENG, BRENDA | reporter.nih.gov |
| Feasibility and initial efficacy of a wheelchair exercise-training intervention for persons with multiple sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 | $52,776 | April 1, 2023 | July 31, 2023 | GEE, STEPHANIE SILVEIRA | reporter.nih.gov |
| Mechanisms of immune-mediated neuronal damage in a mouse model of optic neuritis | NIH | National Eye Institute | 2025 | $51,628 | January 1, 2025 | December 31, 2028 | SOMMERS, KELLI C | reporter.nih.gov |
| Pathogenic Mechanism of Intrathecally Synthesized Immunoglobulins in a Mouse Model of Progressive Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $50,174 | July 22, 2022 | September 21, 2023 | LINZEY, MICHAEL R | reporter.nih.gov |
| Pathological Inflammation Alters Oligodendrocyte Differentiation and Function | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $49,538 | August 15, 2025 | August 14, 2027 | XIONG, YING | reporter.nih.gov |
| Investigating the Role of Slc4a4 in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $49,538 | July 28, 2025 | July 27, 2028 | AILANI, ROSHAN | reporter.nih.gov |
| Stress Biology and Psychosocial stressors as mechanisms for Racial Health Disparities in Neural and Clinical Impairments of Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $47,752 | July 1, 2022 | May 11, 2023 | MOODY, SHANNIN NICOLE | reporter.nih.gov |
| Physical Activity, Vascular Function, and Brain Health in Multiple Sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $47,003 | August 17, 2025 | August 16, 2027 | DUBOSE, NOAH G. | reporter.nih.gov |
| Quantitative MRI of Multiple Sclerosis - Resubmission - 1 | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $45,686 | September 22, 2020 | November 30, 2021 | HASSE, ADAM JAMES | reporter.nih.gov |
| Protective role of dectin-1 signaling in an animal model of Multiple Sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $44,577 | August 1, 2018 | April 30, 2022 | DEERHAKE, MARION ELIZABETH | reporter.nih.gov |
| Characterizing Shared Features of Innate Immune Cells across Neurodegenerative Diseases using Single Cell Expression and Chromatin Accessibility Data | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $43,635 | January 16, 2021 | May 31, 2022 | KUCHROO, MANIK | reporter.nih.gov |
| The oral microbiome as a window into the pathobiology of multiple sclerosis, leading to new ideas for personalized microbial therapies | NIH | National Institute of Dental & Craniofacial Research | 2023 | $43,630 | December 1, 2023 | November 30, 2024 | FITZJERRELLS, RACHEL LYNN | reporter.nih.gov |
| Neurophysiologic and Connectivity Changes Associated with SlowedProcessing Speed and Working Memory Impairments in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $41,660 | May 15, 2020 | May 14, 2022 | ZUPPICHINI, MARK DANIEL | reporter.nih.gov |
| Investigating a Role for Antigen Presentation by Enteric Glial Cells in Experimental Autoimmune Encephalomyelitis | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $40,205 | April 1, 2024 | March 31, 2025 | BROWN, RYAN | reporter.nih.gov |
| Interferon-gamma mediates neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy (MSA) | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $39,984 | July 1, 2023 | June 30, 2024 | CORBIN-STEIN, NICOLE | reporter.nih.gov |
| JAK1 Signaling in Neuroinflammation | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $39,583 | June 1, 2020 | October 1, 2021 | SIMS, SAVANNAH GRAHAM | reporter.nih.gov |
| Translating Genetic Risk Factors to Therapies: From Big Data to Druggable Targets | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $38,874 | July 1, 2021 | March 31, 2022 | SHAW, BENJAMIN C. | reporter.nih.gov |
| The impact of immunoglobulin induced interferon response on remyelination | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $38,093 | September 1, 2025 | August 31, 2027 | PEET, GRAHAM C | reporter.nih.gov |
| Elucidating the role of APCs in immune tolerance during direct lymph node immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $36,718 | August 1, 2020 | July 31, 2022 | EPPLER, HALEIGH | reporter.nih.gov |
| Patient-Centered Neurological Evaluation of Functional MRI Outcomes in Multiple Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $34,859 | June 1, 2025 | May 31, 2027 | WITT, ATLEE | reporter.nih.gov |
| Interrogating immune signatures in the thoracic duct of patients with multiple sclerosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $34,290 | September 1, 2023 | August 31, 2024 | ESPINOZA, DIEGO ALEXANDER | reporter.nih.gov |
Organizations
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 209 | $94,072,438 | 0 | $0 |
| 2024 | 216 | $90,698,264 | 0 | $0 |
| 2023 | 217 | $85,026,876 | 0 | $0 |
| 2022 | 258 | $98,043,820 | 0 | $0 |
| 2021 | 257 | $101,524,932 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.